Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
Notwendige Cookies
Diese Cookies sind für das Funktionieren des Logins und die Speicherung der Cookie-Einstellungen erforderlich und können deshalb nicht deaktiviert werden.
GlobeNewswire verbreitet Pressemeldungen und Pflichtmitteilungen von börsennotierten Gesellschaften. Der Großteil der Mitteilungen stammt von Unternehmen aus Nordamerika, Großbritannien und den nordeuropäischen Ländern.
(Oslo, 25 March 2026) The Board of Directors of Hexagon Purus ASA (“the Company”) has approved the Company's Integrated Annual and Sustainability Report for 2025....
The stunning Lakeview Estates model home, which comes fully furnished, is among the final homes available for sale in this award-winning community The stunning Lakeview Estates model home, which comes fully furnished, is among the final homes available for sale in this award-winning community...
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial....
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that efficacy is independent of the number of prior lifetime treatment failures in a forthcoming issue of Psychopharmacology Bulletin....
RALEIGH, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced the release of its 2025 Sustainability Report covering the calendar year 2025....
Space-Saving 35 mm by 14.5 mm by 28 mm Device Offers Linearity Down to ± 1 %, Resolution of 12 µm, and a Lifespan of > 10 Million Cycles Space-Saving 35 mm by 14.5 mm by 28 mm Device Offers Linearity Down to ± 1 %, Resolution of 12 µm, and a Lifespan of > 10 Million Cycles...
Zitat des Tages: Frauen sprechen lieber als Männer. Trotzdem sind sie die schlechteren Redner, weil sie keinen Sinn für Demagogie haben. - Dame Edith Sitwell